Distinct evolutionary mechanisms for genomic imbalances in high-risk and low-risk neuroblastomas

David Gisselsson*1,2, Gisela Lundberg1, Ingrid Øra3 and Mattias Höglund1

Address: 1Department of Clinical Genetics, Lund University Hospital, SE 221 85 Lund, Sweden, 2Department of Pathology, Lund University Hospital, SE 221 85 Lund, Sweden and 3Department of Paediatric Haematology and Oncology, Lund University Hospital, SE 221 85 Lund, Sweden

Email: David Gisselsson* - david.gisselsson@med.lu.se; Gisela Lundberg - gisela_lundberg@yahoo.se; Ingrid Øra - i.ora@amc.uva.nl; Mattias Höglund - mattias.hoglund@med.lu.se

* Corresponding author

Abstract

Background: Neuroblastoma (NB) is the most common extracranial solid tumour of childhood. Several genomic imbalances correlate to prognosis in NB, with structural rearrangements, including gene amplification, in a near-diploid setting typically signifying high-risk tumours and numerical changes in a near-triploid setting signifying low-risk tumours. Little is known about the temporal sequence in which these imbalances occur during the carcinogenic process.

Methods: We have reconstructed the appearance of cytogenetic imbalances in 270 NBs by first grouping tumours and imbalances through principal component analysis and then using the number of imbalances in each tumour as an indicator of evolutionary progression.

Results: Tumours clustered in four sub-groups, dominated respectively by (1) gene amplification in double minute chromosomes and few other aberrations, (2) gene amplification and loss of 1p sequences, (3) loss of 1p and other structural aberrations including gain of 17q, and (4) whole-chromosome gains and losses. Temporal analysis showed that the structural changes in groups 1–3 were acquired in a step-wise fashion, with loss of 1p sequences and the emergence of double minute chromosomes as the earliest cytogenetic events. In contrast, the gains and losses of whole chromosomes in group 4 occurred through multiple simultaneous events leading to a near-triploid chromosome number.

Conclusion: The finding of different temporal patterns for the acquisition of genomic imbalances in high-risk and low-risk NBs lends strong support to the hypothesis that these tumours are biologically diverse entities, evolving through distinct genetic mechanisms.

Background

Neuroblastoma (NB) originates from the postganglionic cells of the sympathetic nervous system and is the most common extracranial solid tumour of childhood. Four of five children with NB are diagnosed before 4 years of age and it is the most common tumour in infancy, becoming less frequent in each succeeding year. In spite of vast knowledge about the biology of NB, the long-term survival is still less than 30% for children with high-risk tumours [1]. It is a well-known fact that acquired chromosome changes in neoplastic cells contribute to tumour development. This is well illustrated by NB, where several genomic imbalances have been shown to correlate to prognosis. Amplification of the MYCN oncogene in dou-
ble minute chromosomes (dmin) or homogeneously staining regions (hsr), loss of heterozygosity for the short arms of chromosomes 1 (1p) and 3 (3p) and the long arm of chromosome 11 (11q), and gain of sequences from 17q have all been shown to predict a poor prognosis [2-5]. On the other hand, tumours with hyperdiploid or near-triploid karyotypes dominated by whole-chromosome gains and losses have a considerably better prognosis and may even undergo spontaneous regression [3,6,7]. The former pattern of imbalances is generally more common in patients above 12–18 months of age, whereas the latter one is more common in younger children.

Despite the importance of genomic imbalances for the clinical outcome of NB, little is yet known about the processes through which such imbalances are acquired. We have previously established a method for statistically assessing the relative time of occurrence (TO) of cytogenetic aberrations in tumours by determining the degree of cytogenetic complexity at which each aberration typically occurs [8-12]. The possibility to screen for genomic imbalances in NB at a high resolution level has improved dramatically over the last few years, with the introduction of array-based whole-genome screening techniques [3,13-15]. However, with some notable exceptions [15], studies of NB by such high-resolution screening methods have so far only included a relatively small number of cases. In contrast, several hundred NBs have been analysed by chromosome banding methodology and curated karyotypes of published cases are available in a public database [16]. In order to maximise the number of cases used for temporal reconstruction, we therefore chose to analyse data from this latter source, first by grouping imbalances frequently occurring together, and then by establishing their relative order within each group. We finally correlated these abnormalities to basic clinical parameters. Our data indicate that near-diploid, highly aggressive, tumours and near-triploid, less aggressive, tumours acquire their respective chromosome aberrations through different temporal processes: While the near-diploid tumours accumulate clonal abnormalities through sequential genomic rearrangements, the second group of tumours obtains their near-triploid status by multiple simultaneous events.

Methods

General strategy
Karyotypes from 270 NB patients available in the Mitelman Database of Chromosome Aberrations in Cancer were downloaded as text files. ISCN karyotypes [17] were converted into binary data sets denoting the status of each chromosome band as 1 if gained, -1 if lost, and 0 if neither gained nor lost. [18]. Whole genome profiles of all chromosomes were then created and chromosome segments gained or lost in >5% of the tumours were selected for further analysis (Table 1). In the event that one or more segments of a chromosome deviated >5% units from the whole-chromosome profile, these segments were scored separately from the whole-chromosome imbalances. Each karyotype was then assessed for the presence or absence of the selected imbalances. The number of imbalances per tumour (NIPT) was calculated and cases with at least one of the chosen imbalances were selected for further analysis, resulting in 259 cases. Also, if available, the age of the patient as well as tumour stage according to the International Neuroblastoma Staging System [19] was retrieved from the original publication of each case. Age and stage were combined into a simplified clinical risk stratification as follows: patients with stage 1-, 2- and 4s-disease were assigned low risk irrespective of age, whereas patients with stage 3-disease irrespective of age and stage 4-disease <1 years of age were assigned intermediate risk. Stage 4 cases >1 years of age were classified as high risk.

Statistical analyses
To search for possible patterns of correlations between the imbalances, principal component analysis (PCA) was performed using the Statistica software package (Statsoft, Tulsa, OK). PCA is a standard multivariate method frequently used to search for underlying structures in data sets [18]. In short, principal components are linear combinations of the original variables, orthogonal, and ordered with respect to their variance so that the first principal component has the largest variance. To analyse imbalances, these were used as variables and the individual tumours as the observations; this will group imbalances frequently seen in the same tumours. Tumour cases were analysed by using the tumours as variables and the imbalances as cases. This will group tumours with similar karyotypic profiles. The TO was determined essentially as described [8]. Briefly, all tumours with a given imbalance were selected and the distributions of NIPT plotted. The modes of the NIPT distributions were then used as values for TO. To obtain a better estimate of the TO, the selected distributions were re-sampled with replacement (bootstrapped) 1,000 times and the TO scored after each resampling [20]. The mean of the bootstrapped TO values was then used as the TO for the given imbalance and the bootstrapped 25th and 75th percentiles calculated. For the bootstrap estimates, re-sampling software from Resampling Stats (Arlington, VA) was used.

Results

Basic statistics
Of the 270 cases, 59% were near-diploid, 23% were near-triploid, and 15% were near-tetraploid. The remaining 3% either had ploidies defined as intervals spanning different ploidy levels or had multiple clones at different levels. In total, 14 whole-chromosome gains, 21 whole-chromosome losses, two segmental chromosome gains, and four
segmental chromosome losses were found in >5% of the tumours (Table 1). Double minute chromosomes (dmin) and homogeneously staining regions (hsr) were also present in >5% of the karyotypes. One or more of these abnormalities were present in 259 (93%) of the total number of tumours.

**Principal component analysis of imbalances**

To assess whether some of the selected abnormalities preferentially occurred together with one or more other abnormalities, we performed PCA of the karyotypic data. This revealed three distinct clusters of aberrations, one containing all the whole-chromosome gains, a second containing all whole-chromosome losses, and a third containing all imbalances resulting from structural rearrangements, i.e. segmental gains, segmental losses, hsr and dmin (Figure 1). Although the distance between two aberrations in the PCA diagram is ultimately a representation of the correlation between the frequencies of these two abnormalities in any sub-set of tumours, the relationships between the abnormalities were often complex. For example, 1p- and dmin were located outside the main cluster of structural rearrangements and the presence of one of these changes correlated only weakly with the other (r = +0.13; P < 0.01). Of the total 57 cases with dmin, 35 showed 1p- (61%). Conversely, of the 133 cases with 1p-, only 35 (26%) also showed dmin. Hence, the clustering of imbalances into whole-chromosome gains, losses, and structural changes by PCA was not always translatable into straightforward concurrence of abnormalities within cases belonging to the same cluster. Nevertheless, the PCA of genomic imbalances suggested that most NBs could be classified into groups based on the presence in the karyotype of whole-chromosome gains, whole-chromosome losses, or structural changes.

**Principal component analysis of cases**

In order to further explore the subdivision of NB according to cytogenetic imbalances, we performed PCA in the reverse fashion, i.e. using the genomic imbalances as observations and the cases as variables. A scatter plot of all 259 cases according to the two first principal components resulted in four clusters (Figure 2a and 2b; Table 2): (1) those with dmin without 1p-, (2) those with 1p- as well as dmin or hsr, (3) those with 1p- without dmin or hsr, and (4) those with neither 1p- nor dmin. Some structural imbalances other than dmin, hsr, and 1p- also showed dmin. Hence, the clustering of imbalances into whole-chromosome gains, losses, and structural changes by PCA was not always translatable into straightforward concurrence of abnormalities within cases belonging to the same cluster. Nevertheless, the PCA of genomic imbalances suggested that most NBs could be classified into groups based on the presence in the karyotype of whole-chromosome gains, whole-chromosome losses, or structural changes.

---

**Table 1: Relative frequency and age/stage/risk correlates of cytogenetic abnormalities**

| Karyotype features | Frequencies (%) | Overrepresented group (P value) |
|--------------------|----------------|---------------------------------|
| Ploidy level       |                | Age | Stage | Risk |
| 2n                 | 59             |     |      |      |
| 3n                 | 23             | <1 ys (6 × 10⁻⁴) | 1–2 (4 × 10⁻⁵) | L (1 × 10⁻⁶) |
| 4n                 | 15             |     |      |      |
| Whole chromosome gains |               |     |      |      |
| +17                | 15             | <1 ys (3 × 10⁻⁴) | 1–2 (4 × 10⁻⁵) | L (7 × 10⁻⁶) |
| +7                 | 13             |     |      |      |
| +18                | 11             |     |      |      |
| +12                | 10             | <1 ys (3 × 10⁻⁴) | 1–2 (2 × 10⁻⁴) | L (2 × 10⁻⁴) |
| +20                | 9              |     |      |      |
| +21                | 6              |     |      |      |
| +5                 | 6              |     |      |      |
| +11                | 5              |     |      |      |
| +2                 | 5              |     |      |      |
| +1                 | 5              |     |      |      |
| Whole chromosome losses |               |     |      |      |
| -X                 | 21             |     |      |      |
| -11                | 14             |     |      |      |
| -10                | 14             |     |      |      |
| -15                | 14             |     |      |      |
| -19                | 14             |     |      |      |
| -4                 | 14             | 1–2 (5 × 10⁻⁴) | L (5 × 10⁻⁴) |
| -3                 | 12             |     |      |      |
| -9                 | 11             |     |      |      |
| -14                | 11             |     |      |      |
| -17                | 11             |     |      |      |
| -22                | 11             |     |      |      |
| -21                | 11             |     |      |      |
| -13                | 10             |     |      |      |
| -16                | 10             |     |      |      |
| -8                 | 9              |     |      |      |
| -6                 | 9              |     |      |      |
| -20                | 9              |     |      |      |
| -5                 | 8              |     |      |      |
| -2                 | 6              |     |      |      |
| -18                | 6              |     |      |      |
| -12                | 5              |     |      |      |
| Partial chromosome gains |         |     |      |      |
| +1q (1p31q44)      | 15             |     |      |      |
| +17q (17q12q25)    | 13             |     |      |      |
| Partial chromosome losses |       |     |      |      |
| 1p- (1p36p11)      | 48             |     |      | H (4 × 10⁻⁴) |
| 11q- (11q23q25)    | 8              |     |      |      |
| 3p- (3p24p12)      | 8              |     |      |      |
| 6p- (6q23q27)      | 6              |     |      |      |
| Gene amplifications |               |     |      |      |
| dmin               | 20             | 1–3 (8 × 10⁻⁴) | H (6 × 10⁻⁴) |
| hsr                | 6              |     |      |      |

Over-representation tested by Chi-Square test with significance level set at P < 0.01. Abbreviations: ys, years; L, low risk; H, high risk; -, not significantly over-represented in any subgroup.
mosomes gains and karyotypes dominated by whole-chromosome losses (Figure 2c and 2d). In group 4, whole chromosome gains were generally much more prevalent than in the other three groups, whereas group 3 was generally dominated by losses. Groups 1 and 2 showed only little variability along the third principal component, most probably because whole chromosome imbalances were rare in both these subgroups.

**Correlation to age, stage, and risk classification**

Age and tumour stage could be identified in 252 and 217 cases, respectively. In many of the original publications, age was given in full years only and more refined age subdivision could therefore not be made. Age and stage were combined into a simplified clinical risk classification as described in Materials and Methods. This resulted in the identification of 48 low-risk, 24 intermediate-risk, and 146 high-risk patients. To establish whether any of the selected imbalances were present more or less often than expected from a random distribution we first calculated the expected number of tumours with a certain imbalance for each subgroup and compared these distributions to the true distributions in our material. Suspected over/under-representations were tested with Chi-square test.

**Table 2: Cytogenetic subgroups derived from PCA**

| Chromosomal imbalances | Ip- negative dmin positive | Ip- positive dmin/hsr positive | Ip- positive dmin/hsr negative | Ip- negative dmin/hsr negative |
|------------------------|----------------------------|-------------------------------|-------------------------------|-------------------------------|
| Number of cases        | 21                         | 40                            | 93                            | 97                            |
| Whole chromosome gains |                            |                               |                               |                               |
| +1                     | 0                          | 8                             | 3                             | 9                             |
| +2                     | 0                          | 3                             | 3                             | 10                            |
| +3                     | 5                          | 0                             | 2                             | 10                            |
| +5                     | 0                          | 3                             | 3                             | 12                            |
| +6                     | 0                          | 0                             | 6                             | 13                            |
| +7                     | 5                          | 3                             | 11                            | 25                            |
| +8                     | 0                          | 3                             | 5                             | 12                            |
| +9                     | 0                          | 5                             | 4                             | 16                            |
| +10                    | 10                         | 0                             | 3                             | 10                            |
| +12                    | 0                          | 3                             | 8                             | 20                            |
| +13                    | 5                          | 3                             | 5                             | 18                            |
| +17                    | 5                          | 0                             | 10                            | 32                            |
| +18                    | 5                          | 3                             | 12                            | 18                            |
| +20                    | 0                          | 5                             | 10                            | 15                            |
| +21                    | 5                          | 3                             | 2                             | 14                            |
| Whole chromosome losses|                            |                               |                               |                               |
| -2                     | 0                          | 8                             | 4                             | 10                            |
| -3                     | 0                          | 5                             | 16                            | 16                            |
| -4                     | 0                          | 5                             | 13                            | 24                            |
| -5                     | 0                          | 8                             | 5                             | 12                            |
| -6                     | 5                          | 5                             | 9                             | 13                            |
| -8                     | 10                         | 8                             | 10                            | 12                            |
| -9                     | 0                          | 8                             | 13                            | 15                            |
| -10                    | 5                          | 13                            | 15                            | 19                            |
| -11                    | 0                          | 8                             | 14                            | 24                            |
| -12                    | 0                          | 0                             | 6                             | 9                             |
| -13                    | 0                          | 3                             | 16                            | 11                            |
| -14                    | 10                         | 8                             | 13                            | 12                            |
| -15                    | 0                          | 10                            | 19                            | 16                            |
| -16                    | 5                          | 8                             | 6                             | 19                            |
| -17                    | 5                          | 13                            | 12                            | 12                            |
| -18                    | 0                          | 5                             | 4                             | 9                             |
| -19                    | 10                         | 5                             | 13                            | 22                            |
| -20                    | 5                          | 5                             | 9                             | 12                            |
| -21                    | 5                          | 8                             | 13                            | 14                            |
| -22                    | 5                          | 5                             | 13                            | 15                            |
| X                      | 14                         | 5                             | 27                            | 29                            |
| Partial chromosome gains|                          |                               |                               |                               |
| +1q                    | 19                         | 13                            | 13                            | 21                            |
| +17q                   | 5                          | 8                             | 20                            | 12                            |
| +1q (1p31q44)          |                             |                               |                               |                               |
| +17q (17q32q25)        |                             |                               |                               |                               |
| Partial chromosome losses|                          |                               |                               |                               |
| +1p- (1p36p11)         | 0                          | 100                           | 100                           | 0                             |
| +3p- (3p26p12)         | 10                         | 5                             | 6                             | 12                            |
| +6q- (6q23q27)         | 5                          | 5                             | 9                             | 6                             |
| +11q (11q23q25)        | 5                          | 3                             | 10                            | 11                            |
| Gene amplifications    |                            |                               |                               |                               |
| hsr                    | 0                          | 23                            | 0                             | 0                             |
| dmin                   | 100                        | 90                            | 0                             | 0                             |

*Imbalances present at a frequency of 10% or more are in bold type; imbalances included in sub-group definitions are underlined.*
conomies characteristic of group 4) were all over-represented in patients less than 1 year of age (Figure 3). The same abnormalities were over-represented in tumours of lower stages (1–2) and in low-risk tumours (Figure 2e and 2f). In addition, loss of whole chromosome 4 was over-represented in low-stage (1–2) and low-risk tumours. In contrast, 1p- and dmin (characteristic of groups 1–3) were over-represented in high-risk tumours; dmin were also over-represented in patients >1 year and <4 years of age.

**Temporal development of chromosome changes**

The total number of imbalances in a tumour can be used as an approximation of its state of clonal evolution [8-12,18]. Hence, the modal number of imbalances at which a specific cytogenetic abnormality occurs can be used to approximate its time of occurrence (TO) in relation to other abnormalities in the same sample of tumours. The present TO analysis showed that the structural rearrangements appeared in a relatively specific order, initiated by 1p- and dmin (TO = 1–2), followed by +17q, +1q, 3p-, 6q-, hsr (TO = 2–4), and finally by 11q- (TO = 3–6) (Figure 4). For the whole-chromosome changes, the TO values were confined between 8 and 14, with highly overlapping 25th–75th percentile intervals. Accordingly, there was no difference in TO between gains and losses of whole chromosomes. Hence, each whole-chromosome abnormality was most probably acquired together with one or several other abnormalities of the same type.

**Discussion**

Studies of the tumour genome by chromosome banding analysis suffer from several shortcomings, e.g. difficulties in obtaining a sufficient number of mitotic cells for analysis, overgrowth of normal cells in tissue culture, poor quality of chromosome preparation, and an inherently low resolution. Nevertheless, several large cytogenetic series of NB, some of which have been complemented by multicolour fluorescence in situ hybridisation analysis,
have been reported with a high frequency of cases showing cytogenetic abnormalities and with detailed karyotype descriptions [6,21-25]. In the present study, we have summarised the published cytogenetic data in NB and performed a comprehensive and unbiased statistical analyses. PCA of chromosomal imbalances revealed three distinct clusters of imbalances that tended to occur together in the same tumours, i.e. whole-chromosome gains, whole-chromosome losses, and structural changes. Of the structural changes, 1p- and dmin were by far the most common, occurring in 48% and 20% of the tumours, respectively. Indeed, when PCA of the tumour cases was performed, these two changes largely dominated the first two principal components. The third principal component was dominated by the spectrum of whole chromosome changes. In summary, the PCAs indicated that the accumulated cytogenetic data could warrant sub-classification of NBs into at least four groups, i.e. those characterised by (1) dmin and few other imbalances, (2) dmin, 1p-, and few other imbalances, (3) 1p-, other structural changes such as +17q, and whole chromosome losses, and finally (4) whole-chromosome gains and losses. Groups 1–3 were dominated by the structural abnormalities associated with high-risk tumours in the present study (dmin/hsr, 1p), while group 4 was dominated by numerical abnormalities associated with low-risk tumours (+9, +12, +17, and -4).

Several authors have suggested that NB can be sub-divided into at least two biological entities, reflecting the heterogeneous scenario observed in NB patients [26]. The first group is characterised by a near-diploid karyotype and genetic imbalances based on structural cytogenetic changes. Among these, the NB with MYCN amplification, also often showing 1p-, generally present with high-stage disease and are rapidly progressive, whereas the tumours without MYCN amplification but with other structural changes such as loss of heterozygosity for 11q typically occur in patients with slowly progressive but often fatal disease. These two subgroups most closely resemble groups 1–2 and 3, respectively in the present study. The other main biological group is characterised by a near-triploid karyotype with few structural chromosome changes, occurring in infants with confined disease and a very good prognosis. This group corresponds to our group 4. Hence, despite its inherent methodological limitations, the

Figure 3
Frequencies across age groups. Lines represent triploid cases, cases with +9, +12, +17, -4, and dmin in patients aged 0 (below 1), 1, 2, 3, and above 3 years of age.

Figure 4
Temporal analysis. The estimated TO values are indicated by open squares. The range of the 25th and 75th quartiles is indicated by filled boxes. The imbalances are ordered with respect to their estimated TO values.
present study identified clinico-genetic sub-groups that were largely similar to those identified by other recent studies using comparative genome hybridisation and oligonucleotide arrays [3,15].

It has been suggested that diploid and triploid NB may arise from a common tetraploid precursor undergoing tripolar cell division [26,27]. The first type of daughter cell (2n) may give rise to the near-diploid, typically aggressive, tumours characterised by structural chromosomal changes, particularly 1p-, 11q-, +17q, and dmin (our groups 1–3). The second type of daughter cell (3n) may evolve into the near-triploid, typically indolent, tumours harbouring whole-chromosome changes, such as +9, +12, and +17 (our group 4). Although a highly attractive hypothesis, little empirical data have so far been presented to substantiate that these two biological NB entities in fact evolve through different evolutionary pathways. If the near-diploid tumours were actually derived from a tripolar tetraploid mitosis, segregating into haploid sets as originally suggested by Kaneko and Knudson [27], this could result in three possible sex chromosome complements in the resulting 2n cells, i.e. XY, XX, and YY. Of these, YY would be twice as probable as each of the two other two. It can be further argued that the YY cells, having nullisomy for the X chromosome, are not likely to survive. Hence, if the 2n tumours resulted from a tripolar cell division of a tetraploid cell, this would imply that 1/3 of the NB with 2n ploidy in male patients should have an XX chromosome complement. None of the 90 karyotypes from male patients with 2n tumours in the present series, showed such sex-reversal. However, this chain of reasoning assumes that somatic cell feminisation would not be lethal on the cellular level, which cannot be excluded at present. Furthermore, it does not rule out that tripolar division of a tetraploid cell lies behind the generation of near-triploid tumours, in which such somatic sex reversal would not occur if one assumed segregation into haploid sets.

In the present study we used the number of chromosome imbalances at which a certain chromosomal aberration typically occurred to model the evolution of genomic changes in NB. This approach has previously been used to delineate the temporal development of chromosome aberrations in several other tumours [9-11,28,29]. Our analysis showed that the structural changes occurred in a step-wise fashion, with loss of 1p sequences and the emergence of double minute chromosomes as the earliest cytogenetic events, followed by gain of 1q and 17q, loss of 3p and 6q, acquisition of homogeneously staining regions, and finally loss of 11q. In contrast, the gains and losses of whole chromosomes occurred more or less simultaneously, in a fashion similar to that suggested for the acquisition of whole-chromosome gains in hyperdiploid childhood leukemias [30]. This supports the notion that the numerical chromosome changes in 3n NB may arise through a single rare event, such as an asymmetrical mitotic cell division. In contrast, the 2n tumours appear to develop through the sequential acquisition of structural changes. Such a step-wise evolution of genome imbalances has been found in many common carcinomas, such as colorectal cancer, breast cancer, ovarian cancer, and bladder cancer [8]. It is possible that this step-wise acquisition of clonal changes reflects genome plasticity, which might explain why 2n tumours are more resistant to treatment than 3n tumours.

Conclusion
Our finding of different dynamics for the acquisition of chromosome changes in the two main biological subsets of NB, taken together with the PCA classification of tumours into those with structural and those with numerical changes, lends strong support to the hypothesis that high-risk and low-risk NBs are biologically diverse entities, evolving through at least two distinct genetic mechanisms.

Abbreviations
2n – near-diploid; 3n – near-triploid; dmin – double minute chromosomes; hsr – homogeneously staining regions; NIPT – number of imbalances per tumour; NB – neuroblastoma; TO – time of occurrence.

Competing interests
The author(s) declare that they have no competing interests.

Authors’ contributions
DG and MH collected cytogenetic data, performed statistical analyses and drafted the manuscript. GL and IO collected clinical data and drafted the manuscript. All authors have read and approved the final manuscript.

Acknowledgements
The authors are grateful to Professor Fredrik Mertens for critical reading of the manuscript. The study was supported by the Swedish Children’s Cancer Foundation, the Gunnar Nilsson Cancer Foundation, the Sward Foundation, the Crafoord Foundation, the Swedish Medical Society, the Lund University Hospital Donation Funds, the Swedish Cancer Foundation and the Swedish Research Council.

References
1. Cotterill SJ, Pearson AD, Pritchard J, Foot AB, Roald B, Kohler JA, Imeson J: Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group ‘Survey’ 1982-1992. Eur J Cancer 2000, 36(7):901-908.
2. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D: Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985, 313(18):1111-1116.
3. Spitz R, Oberthuer A, Zapatska M, Brors B, Hero B, Ernestus K, Oestreich J, Fischer M, Simon T, Berthold F: Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90
neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Genes Chromosomes Cancer 2005, 42(12):1194-211.

4. Attiyeh EF, London WB, Mosse YP, Wang Q, Winter C, Khazl D, McGrady PW, Seeger RC, Look AT, Shimada H, Brodeur GM, Cohn SL, Matthay K, Maris JM. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005, 353(21):2243-2253.

5. Bown N, Cotterill S, Lastowska M, O'Neill S, Pearson AD, Plantaz D, Broecke C, De Bie S, De Paepe A, Laureys G, Speleman F, Nicholson J, Bernheim A, Betts DR, Vandesompele J, Van Roy N: Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999, 340(25):1954-1961.

6. Kaneko Y, Kanda N, Maseki N, Sakuraki M, Tsuchida Y, Takeda T, Okabe I, Sakurai M: Different karyotypic patterns in early and advanced stage neuroblastoma. Cancer Res 1987, 47:513-518.

7. Spitz R, Betts DR, Simon T, Boensch M, Oestreicher J, Niggli FK, Erneus-berthold F, Hero B: Favorable outcome of triploid neuroblastomas: a contribution to the special oncogenesis of neuroblastoma. Cancer Genet Cytogenet 2006, 167(1):51-56.

8. Höglund M, Frigyesi A, Sall T, Gisselsson D, Mitelman F: Statistical behavior of complex cancer karyotypes. Genes Chromosomes Cancer 2005, 42(4):327-341.

9. Höglund M, Gisselsson D, Hansen GB, Sall T, Mitelman F: Multivariate analysis of chromosomal imbalances in breast cancer delineates cytogenetic pathways and reveals complex relationships among imbalances. Cancer Res 2002, 62(9):2675-2680.

10. Höglund M, Gisselsson D, Hansen GB, Sall T, Mitelman F: Ovarian carcinoma develops through multiple modes of chromosomal evolution. Cancer Res 2003, 63(12):3378-3385.

11. Höglund M, Gisselsson D, Hansen GB, Sall T, Mitelman F, Nelibert M: Dissecting karyotypic patterns in colorectal tumors: two distinct but overlapping pathways in the adenoma-carcinoma transition. Cancer Res 2002, 62(20):5939-5946.

12. Höglund M, Gisselsson D, Mandal N, Johansson B, Mertens F, Mitelman F, Sall T: Multivariate analyses of genomic imbalances in solid tumors reveal distinct and converging pathways of karyotypic evolution. Genes Chromosomes Cancer 2001, 31(2):156-171.

13. Hiyama E, Yamaoka H, Kamimatsumi A, Onitake Y, Hiyama K, Nishiyama M, Sueda T: Single nucleotide polymorphism array analysis to predict clinical outcome in neuroblastoma patients. J Pediatr Surg 2006, 41(12):2032-2036.

14. George KE, Attiyeh EF, Li S, Moreau LA, Neuberg D, Li C, Fox EA, Meyerson M, Diller L, Fortina P, Look AT, Maris JM: Genome-Wide Analysis of Neuroblastomas using High-Density Single Nucleotide Polymorphism Arrays. PLoS ONE 2007, 2:e255.

15. Vandesompele J, Baudis M, De Preter K, Van Roy N, Ambros P, Bown N, Brinkschmidt C, Christiansen H, Combaret V, Lastowska M, Nicholson J, Omeara A, Plantaz D, Stallings R, Brichta B, Van den Broecke C, De Bie S, De Peae A, Laureys G, Speleman F: Unequivocal delineation of clinogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol 2005, 23(10):2280-2299.

16. Mitelman F, Johansson B, Mertens F: Mitelman Database of Chromosome Aberration in Cancer. http://cgap.nci.nih.gov/Chromosomes/Mitelman/; 2007.

17. Shaffer LG, Tommerup N: ISCN: An International System for Human Cytogenetic Nomenclature. 2005.

18. Höglund M, Gisselsson D, Sall T, Mitelman F: Coping with complexity. multivariate analysis of tumor karyotypes. Cancer Genet Cytogenet 2002, 135(3):103-109.

19. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, et al.: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993, 11(8):1466-1477.

20. Mooney C, Duval R: Bootstrapping: A nonparametric approach to statistical inference. In Sage University Paper Series on Quantitative Applications in the Social Sciences Volume 07. Issue 095. Thousand Oaks, CA, Sage; 1993.

21. Hayashi Y, Inaba T, Hanada R, Yamamoto K: Chromosome findings and prognosis in 15 patients with neuroblastoma found by YMA mass screening. J Pediatr 1988, 112(4):567-571.